SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
PSA Response Improvement: Promising Data from Pluvicto in mHSPC Treatment
New data from the PSMAddition study indicate that Pluvicto combined with standard of care, consisting of an androgen receptor pathway inhibitor plus androgen deprivation therapy, produced a 58% lower risk of prostate-specific antigen progression compared with standard of care alone. Patients rece...
Financing Boosts Vaccine Manufacturing Africa: New Facility to Enhance Local Production Capacity
In a major step forward for vaccine manufacturing Africa, Biovac has secured a financing package from the International Finance Corporation (IFC), the EIB Group, and the European Commission to build the continent’s first end-to-end multi-vaccine production facility.
Landmark Funding ...
Portugal’s MAP02 Medication Adherence Initiative: Enhancing Therapeutic Compliance through ...
MAP02 Medication Adherence stands out as Portugal’s latest digital solution for supporting elderly patients and those with psychomotor challenges who struggle with consistent medication use. Coordinated by the Polytechnic of Leiria through its ciTechCare research unit, the platform merges smart h...